Ardelyx (ARDX) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $74.1 million, a 61% year-over-year increase, driven by strong growth in IBSRELA and XPHOZAH sales, and a $5 million milestone from China for tenapanor approval.

• IBSRELA net sales were $44.4 million (up 57% YoY), with strong prescription demand despite typical Q1 market contraction.

• XPHOZAH net sales reached $23.4 million (up 55% YoY, or 30% excluding a one-time $3.8 million returns reserve release), with growth partially offset by Medicare Part D changes.

• Net loss for Q1 2025 was $41.1 million ($0.17/share), up from $26.5 million ($0.11/share) in Q1 2024, reflecting increased SG&A and R&D expenses.

• Ended Q1 with $214 million in cash, cash equivalents, and short-term investments, down from $250.1 million at year-end 2024.

Financial highlights

• Total Q1 2025 revenue: $74.1 million, up from $46 million in Q1 2024, driven by higher product and milestone revenue.

• IBSRELA net sales: $44.4 million (+57% YoY); XPHOZAH net sales: $23.4 million (+55% YoY, +30% excluding reserve release).

• Gross-to-net deduction for IBSRELA: 34.8%; for XPHOZAH: 18% (32% excluding reserve release); long-term guidance for both is 30% ±5%.

• R&D expenses: $14.9 million (up from $10.6 million YoY); SG&A: $83.2 million (up from $53 million YoY), mainly due to commercialization costs.

• Net loss: $41.1 million ($0.17/share) vs. $26.5 million ($0.11/share) in Q1 2024.

Outlook and guidance

• Reaffirmed 2025 IBSRELA net sales guidance of $240–$250 million.

• XPHOZAH peak annual net sales expected to reach $750 million, assuming no Medicare coverage.

• IBSRELA peak annual net sales expected to exceed $1 billion.

• No formal 2025 revenue guidance for XPHOZAH yet due to ongoing market disruption.

• Management expects continued operating losses as investments in commercialization and pipeline development persist.